190 results
8-K
EX-10.1
SRNEQ
Sorrento Therapeutics, Inc.
3 Nov 23
Entry into a Material Definitive Agreement
5:31pm
8-K
EX-10.1
SRNEQ
Sorrento Therapeutics, Inc.
26 Sep 23
Entry into a Material Definitive Agreement
4:54pm
8-K
EX-10.1
SRNEQ
Sorrento Therapeutics, Inc.
10 Aug 23
Entry into a Material Definitive Agreement
4:14pm
8-K
EX-10.1
SRNEQ
Sorrento Therapeutics, Inc.
7 Jul 23
Entry into a Material Definitive Agreement
9:49pm
8-K
EX-10.2
SRNEQ
Sorrento Therapeutics, Inc.
7 Jul 23
Entry into a Material Definitive Agreement
9:49pm
8-K
EX-10.1
8gcol5yxx30jve
30 Mar 23
Sorrento Therapeutics, Inc. Receives Final Court Approval for $75 Million Debtor-In-Possession Financing
9:39pm
8-K
EX-10.1
0cvwzlspxjodu kice
16 Dec 22
Departure of Directors or Certain Officers
4:10pm
425
EX-10.2
086otueeorop079 p72q
13 Sep 22
Business combination disclosure
6:15pm
425
EX-10.3
zuoxuo1rydr
13 Sep 22
Business combination disclosure
6:15pm
425
EX-10.1
80o20s
13 Sep 22
Business combination disclosure
6:15pm
8-K
EX-10.3
7bnj nmu1sriflj0u9o
13 Sep 22
Entry into a Material Definitive Agreement
6:14pm
8-K
EX-10.1
t6sp02gf4 9yjr
13 Sep 22
Entry into a Material Definitive Agreement
6:14pm
8-K
EX-10.2
cwwbki fghnvjh2z
13 Sep 22
Entry into a Material Definitive Agreement
6:14pm
8-K
EX-10.1
11l0 96beo7zte7bh
3 Jun 22
Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes
9:00am
8-K
EX-10.2
qnkk43um5t db
28 Apr 22
Departure of Directors or Certain Officers
9:00am
8-K
EX-10.1
anrpuo
28 Apr 22
Departure of Directors or Certain Officers
9:00am
425
EX-10.3
vw4 91bmxg
18 Mar 22
Business combination disclosure
9:03am